PR1 is an HLA-A2 restricted AML nonapeptide derived from neutrophil elastase (NE) and proteinase-3 (P3), which offers AML specificity but is only present in patients expressing HLA-A2 [58]. This evidence concerns the gene TMEM37 and acute myeloid leukemia.